Skip to main content
SpringerLink
Log in

Theranostik von soliden Tumoren: Renaissance eines alten Konzepts

Theranostics of solid tumors: renaissance of a longstanding concept

  • Topic
  • Published:
best practice onkologie Aims and scope

Zusammenfassung

Obwohl der Überbegriff Theranostik, ein Schachtelwort aus „therapy“ und „diagnostic“, erst 1998 durch John Funkhouser eingeführt wurde, wird das ihm zugrunde liegende Konzept der Verwendung von mit Radioisotopen verschiedener Art präparierten Biomarkern zu diagnostischen oder therapeutischen Zwecken bereits seit den 1940er-Jahren in der Nuklearmedizin angewandt. Der vorliegende Beitrag gibt einen kurzen Überblick über die Historie und die derzeitigen Anwendungsgebiete sowie einen Ausblick in die Zukunft der Nuklearmedizin sowie nuklearmedizinischer Therapien im Bereich der Onkologie.

Abstract

Although the modern term “theranostic,” a combination of “therapy” and “diagnostic,” was introduced by John Funkhouser in 1998, the underlying concept of using biomarkers prepared with various types of radioisotopes for diagnostic or therapeutic purposes dates back to the 1940s. This article intends to give a brief overview of the history and current areas of application of nuclear medicine as well as future perspectives in the field, including nuclear medicine-based cancer treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Literatur

  1. Ahmadzadehfar H, Albers P, Bockisch A et al (2018) Lutetium-177-PSMA radioligand therapy : consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Dusseldorf, Essen, and cologne and the MDK Nordrhein. Urologe A 57:709–713

    Article  CAS  PubMed  Google Scholar 

  2. Ahmadzadehfar H, Rahbar K, Kurpig S et al (2015) Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res 5:114

    PubMed  Google Scholar 

  3. Claringbold PG, Turner JH (2016) Pancreatic neuroendocrine tumor control: durable objective response to combination 177Lu-Octreotate-capecitabine-temozolomide radiopeptide chemotherapy. Neuroendocrinology 103:432–439

    Article  CAS  PubMed  Google Scholar 

  4. Culp MB, Soerjomataram I, Efstathiou JA et al (2019) Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. https://doi.org/10.1016/j.eururo.2019.08.005

    Article  PubMed  Google Scholar 

  5. Demirci E, Sahin OE, Ocak M et al (2016) Normal distribution pattern and physiological variants of 68 Ga-PSMA-11 PET/CT imaging. Nucl Med Commun 37:1169–1179

    Article  CAS  PubMed  Google Scholar 

  6. Dietlein M, Grunwald F, Schmidt M et al (2016) Radioiodine therapy for benign thyroid diseases (version 5). German Guideline. Nuklearmedizin 55:213–220

    Article  PubMed  Google Scholar 

  7. Erbas B, Tuncel M (2016) Renal function assessment during peptide receptor radionuclide therapy. Semin Nucl Med 46:462–478

    Article  PubMed  Google Scholar 

  8. Fahey FH, Grant FD, Thrall JH (2017) Saul Hertz, MD, and the birth of radionuclide therapy. EJNMMI Phys 4:15

    Article  PubMed  PubMed Central  Google Scholar 

  9. Fendler WP, Kratochwil C, Ahmadzadehfar H et al (2016) 177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer. Nuklearmedizin 55:123–128

    Article  PubMed  Google Scholar 

  10. Kesler M, Levine C, Hershkovitz D et al (2018) (68)Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: a prospective pilot study. J Nucl Med. https://doi.org/10.2967/jnumed.118.214833

    Article  PubMed  Google Scholar 

  11. Kratochwil C, Fendler WP, Eiber M et al (2019) EANM procedure guidelines for radionuclide therapy with (177)Lu-labelled PSMA-ligands ((177)Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-019-04485-3

    Article  PubMed  PubMed Central  Google Scholar 

  12. Kratochwil C, Flechsig P, Lindner T et al (2019) (68)ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med 60:801–805

    Article  PubMed  PubMed Central  Google Scholar 

  13. Krenning EP, Bakker WH, Breeman WA et al (1989) Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1:242–244

    Article  CAS  PubMed  Google Scholar 

  14. Langbein T, Chausse G, Baum RP (2018) Salivary gland toxicity of PSMA radioligand therapy: relevance and preventive strategies. J Nucl Med 59:1172–1173

    Article  CAS  PubMed  Google Scholar 

  15. Leitlinienprogramm-Onkologie (2019) S3 Leitlinie Prostatakarzinom (Version 5.1, 2019). In, www.leitlinienprogramm-onkologie.de

  16. Levine R, Krenning EP (2017) Clinical history of the theranostic radionuclide approach to neuroendocrine tumors and other types of cancer: historical review based on an interview of Eric P. Krenning by Rachel Levine. J Nucl Med 58:3S–9S

    Article  CAS  PubMed  Google Scholar 

  17. Lindner T, Loktev A, Altmann A et al (2018) Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med 59:1415–1422

    Article  CAS  PubMed  Google Scholar 

  18. Maurer T, Robu S, Schottelius M et al (2019) (99m)technetium-based prostate-specific membrane antigen-radioguided surgery in recurrent prostate cancer. Eur Urol 75:659–666

    Article  PubMed  Google Scholar 

  19. Muller SP, Ezziddin S, Antoch G et al (2017) Selective intraarterial radiotherapy (SIRT) of malignant liver tumors. Nuklearmedizin 56:162–170

    Article  PubMed  Google Scholar 

  20. Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213–223

    Article  CAS  PubMed  Google Scholar 

  21. Rahbar K, Bodei L, Morris MJ (2019) Is the “VISION” of radioligand therapy for prostate cancer becoming reality? An overview of the phase III trial and the importance for the future of theranostics. J Nucl Med. https://doi.org/10.2967/jnumed.119.234054

    Article  PubMed  Google Scholar 

  22. Sathekge M, Bruchertseifer F, Knoesen O et al (2019) (225)Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging 46:129–138

    Article  CAS  PubMed  Google Scholar 

  23. Schmidbauer B, Menhart K, Hellwig D et al (2017) Differentiated thyroid cancer-treatment: state of the art. Int J Mol Sci 18(6):E1292

    Article  PubMed  Google Scholar 

  24. Seidlin SM, Marinelli LD, Oshry E (1946) Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid. J Am Med Assoc 132:838–847

    Article  CAS  PubMed  Google Scholar 

  25. Smith M, Parker C, Saad F et al (2019) Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20:408–419

    Article  CAS  PubMed  Google Scholar 

  26. Strosberg J, El-Haddad G, Wolin E et al (2017) Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med 376:125–135

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Strosberg J, Wolin E, Chasen B et al (2018) Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with (177)lu-dotatate in the phase III NETTER‑1 trial. J Clin Oncol 36:2578–2584

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Van Kalmthout LWM, Lam M, De Keizer B et al (2018) Impact of external cooling with icepacks on (68)Ga-PSMA uptake in salivary glands. EJNMMI Res 8:56

    Article  PubMed  PubMed Central  Google Scholar 

  29. Viszeralchirurgie DGFa‑U (2012) Operative Therapie maligner Schilddrüsenerkrankungen

    Google Scholar 

  30. Walenkamp AME, Lapa C, Herrmann K et al (2017) CXCR4 Ligands: the next big hit? J Nucl Med 58:77S–82S

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Nuklearmedizin, Universitätsklinikum Essen, Hufelandstr. 55, 45147, Essen, Deutschland

    P. Sandach, W. P. Fendler & K. Herrmann

Authors
  1. P. Sandach
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. P. Fendler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Herrmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Sandach.

Ethics declarations

Interessenkonflikt

P. Sandach: Sanofi: Honorar als Referent in einem „Schilddrüsensonographiekurs für Hausärzte“ (2,5 h für 250 €) am 26.06.2019, Mitfinanzierung der Teilnahmekosten des „Schilddrüse 2019 – HENNING-Symposium“ vom 10.–12.09.2019, IPSEN: Kostenübernahme für Teilnahme, Unterkunft und Reisekosten bei der „Summer School NEN 2019“ vom 14.–15.06.2019. W.P. Fendler: Consultant für Endocyte und Ipsen. Finanzielle Unterstützung von der Deutschen Forschungsgemeinschaft (DFG), Förderungen: FE1573/1-1/807122 und FE1573/3-1/659216; Mercator Research Center Ruhr (MERCUR, An-2019-0001), IFORES (D/107-81260, D/107-30240), Doktor Robert Pfleger-Stiftung und Wiedenfeld-Stiftung/Stiftung Krebsforschung Duisburg. K. Herrmann: Bayer: Referent und Consultant (2017 und früher), Sirtex: Referent (2017), Adacap/Novartis: Consultant, Referent (aktuell), Curium: Consultant (2017), Endocyte: Consultant (2017), BTG: Referent und Consultant (aktuell), IPSEN: Consultant (aktuell), Siemens Healthineers: Referent (aktuell), GE Healthcare: Referent (2018), Amgen: Consultant (aktuell), Aktien Sofie Biosciences, Geschäftsführer Nuklearmedizin Interaktiv (NMI) GmbH, Chair EANM Oncology and Theranostics Committee.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sandach, P., Fendler, W.P. & Herrmann, K. Theranostik von soliden Tumoren: Renaissance eines alten Konzepts. best practice onkologie 14, 526–534 (2019). https://doi.org/10.1007/s11654-019-00192-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-019-00192-5

Schlüsselwörter

Keywords

Search

Navigation